

Habico Holding A/S

Energivej 15

5260 Odense S

Central Business Registration no. 27 34 71 34

Annual report 2020

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

The Annual General Meeting adopted the annual report on 29 / 06 2021

Chairman of the General Meeting:

Hans Carl Bøgh-Sørensen

Habico Holding A/S

Table of contents

	Page
Company details	3
Statement by Management on the annual report	4
Independent auditor's report	5
Group structure	8
Management's Commentary	9
Income statement for 2020	14
Balance sheet at 31.12.2020	15
Statement of changes in equity for 2020	17
Cash flow statement for 2020	18
Notes	19
Accounting policies	26

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Company details

Company

Habico Holding A/S

Energivej 15

5260 Odense S

Central Business Registration No: 27 34 71 34

Registered in: Odense

Board of Directors

Hans Carl Bøgh-Sørensen, Chairman

Ole Michael Friis, Vice Chairman

Andreas Henrik Bøgh-Sørensen

Anne-Charlotte Bøgh-Sørensen

Birgitte Bøgh-Sørensen

Christian Ulrik Bøgh-Sørensen

Group Executive Board

Birgitte Bøgh-Sørensen, Chief Executive Officer

Company auditors

Deloitte Statsautoriseret Revisionspartnerselskab

Statement by Management on the annual report

The Board of Directors and the Executive Board have today considered and approved the annual report of Habico Holding A/S for the financial year 01.01.2020 - 31.12.2020.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements and the parent financial statements give a true and fair view of the Group's and the Parent's assets, liabilities and financial position at 31.12.2020 and of their financial performance and cash flow's for the financial year 01.01.2020 - 31.12.2020.

We also find that the Management commentary provides a fair statement of developments in the activities and financial situation of the Group and the Parent, financial results for the period, the general financial position of the Group and the Parent, and a description of conditions referred to therein.

We recommend the Annual Report to be approved at the Annual General Meeting.

Odense, 29 June 2021

Executive Board

Birgitte Bøgh-Sørensen
Chief Executive Officer

Board of Directors

Hans Carl Bøgh-Sørensen
Chairman

Ole Michael Friis
Vice Chairman

Andreas Henrik Bøgh-Sørensen

Anne-Charlotte Bøgh-Sørensen Birgitte Bøgh-Sørensen

Christian Ulrik Bøgh-Sørensen

Independent auditor's report

To the shareholders of Habico Holding A/S

Opinion

We have audited the consolidated financial statements and the parent financial statements of Habico Holding A/S for the financial year 01.01.2020 - 31.12.2020, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies, for the Group as well as the Parent, and the consolidated cash flow statement. The consolidated financial statements and the parent financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the consolidated financial statements and the parent financial statements give a true and fair view of the Group's and the Parent's financial position at 31.12.2020, and of the results of their operations and the consolidated cash flows for the financial year 01.01.2020 - 31.12.2020 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the *Auditor's responsibilities for the audit of the consolidated financial statements and the parent financial statements* section of this auditor's report. We are independent of the Group in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the consolidated financial statements and the parent financial statements

Management is responsible for the preparation of consolidated financial statements and parent financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of consolidated financial statements and parent financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements and the parent financial statements, Management is responsible for assessing the Group's and the Parent's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements unless Management either intends to liquidate the Group or the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the consolidated financial statements and the parent financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements and the parent financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements and parent financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements and the parent financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's and the Parent's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Parent's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements and the parent financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements and the parent financial statements, including the disclosures in the notes, and whether the consolidated financial statements and the parent financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the consolidated financial statements and the parent financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements and the parent financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the consolidated financial statements and the parent financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Habico Holding A/S

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the consolidated financial statements and the parent financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 29 June 2021

Deloitte

Statsautoriseret Revisionspartnerselskab
Business Registration No 33 96 35 56

Nikolaj Thomsen


State-Authorised
Public Accountant
MNE Number mne33 276

Jens Rene Serup

State-Authorised
Public Accountant
MNE Number mne45 825

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Group structure



* If no other % is mentioned the owner ship is 100%

Management's Commentary

Financial highlights of the Group

<i>(mio. EUR)</i>	2020	2019	2018	2017	2016
Key figures					
Revenue	1.115,5	981,6	832,9	796,9	725,8
Gross profit	169,4	150,7	131,0	120,4	108,7
Non-recurring costs	-14,2	-0,7	-1,1	0,0	-7,7
Operating profit	38,8	46,8	37,9	33,8	24,3
Net financials	1,4	-0,1	-2,0	-2,6	-5,4
Profit for the year	27,3	34,6	26,9	23,8	12,3
Investments in Tangible fixed assets	19,6	7,9	4,2	4,1	3,0
Inventories	221,0	189,4	140,4	151,4	148,6
Trade receivables	134,7	113,2	101,4	111,7	95,4
Equity	193,2	179,2	154,8	134,1	113,6
Balance sheet total	538,8	447,6	360,3	365,8	350,6
Ratios					
Gross margin (%)	15,2	15,4	15,7	15,1	15,0
Operating margin (%)	3,5	4,8	4,6	4,2	3,3
Equity ratio (%)	35,9	40,0	43,0	36,7	32,4
Return on equity (%)	14,7	20,7	18,6	19,2	11,3

Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.

Habico Holding A/S

Management commentary

Primary activities

Habico Holding A/S is a holding company established and ultimately owned by the Bøgh-Sørensen family. Birgitte and Hans Bøgh-Sørensen founded Orifarm Group A/S.

The Group's primary business activity is being an ambitious operator in the European market for pharmaceuticals through the investment in Orifarm Group A/S, which is the largest supplier of parallel imported pharmaceuticals in Europe.

Secondly the Habico Holding Group invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private, through the ownership of Habico Invest A/S.

Orifarm Group

Orifarm Group consists of two main business areas: Orifarm Parallel Import and Orifarm Generics.

Orifarm Parallel Import

Pharmaceuticals are imported from EU/EEA Member States where original pharmaceutical producers sell their preparations at lower prices, than e.g. the Nordic countries or Germany. This makes it possible to offer original pharmaceuticals at a lower price in other EU countries.

Orifarm Generics

Generic pharmaceuticals can be produced and marketed once the original manufacturer's patent expires and thereby its exclusive rights lapse. Generic competition normally lowers prices on pharmaceuticals significantly which benefits patients and society at large.

Orifarm Generics has established a broad range of generic preparations, including both prescription and over-the-counter products.

Habico Invest

Habico Invest A/S invests across a broad range of asset classes including Private Equity, Real Estate, Investment cars and other financial assets both public and private.

Development in activities and finances

Habico Holding A/S's result for 2020 is better than expected and announced in the Annual Report for 2019.

Orifarm Group

Overall, Orifarm Group achieved new record-breaking levels in key areas like:

- Highest revenue ever in company history
- Highest number of units sold ever in company history
- Highest level of earnings ever in company history excluding non-recurring items.

Habico Invest

Profit arriving from investments also ended with a significant improvement compared to 2019.

Habico Holding A/S

Management commentary

Group

Management is very pleased with the result being the fifth consecutive year where both top-line and profit grew through a dedicated focus on new market entries, organic growth in mature markets, and optimization of internal processes and procedures in both Parallel Import and Generics.

The operating profit includes non-recurring cost of MEUR 14.2 driven by acquisitions and integration costs related thereto.

Outlook

For 2021, Habico Holding A/S expects revenue growth in the range of 10-15% and an operating profit growth in the range of 60-70%.

COVID-19 has not significantly impacted the earnings in 2020. When setting the expectations for activity and earnings for 2021, collected knowledge and experience since March 2020 and until now has been considered.

Particular risks

Operating conditions

To a significant extent, consolidated earnings depend on legislative measures that affect the pricing of pharmaceuticals in both the purchase and the sales countries. Earnings are also affected by measures in the sales countries which are intended to limit the consumption of pharmaceuticals.

For the business area Orifarm Parallel Import, it is Group policy to avoid infringing trademark rights, and the Group is not currently involved in any major pending litigation of this kind.

For the business area Orifarm Generics, the Group policy states that infringing patent rights should be avoided. However, patent holders have a commercial interest in defending market monopolies and manufactures of generic products have an interest in challenging the market at patent expiry. This makes disputes and litigation difficult to avoid. The Group is from time to time involved in pending legal proceedings. The outcome of these may affect earnings.

Financial matters

Habico Holding Group is exposed to fluctuations in foreign exchange rates and interest rate levels. These risks are mitigated through hedge in accordance with the Group's policy. Exchange rate risks are primarily related to the currencies SEK, NOK, CZK, and GBP.

A 1 percentage point change in the interest rate level affects the Group's earnings net by approx. MEUR 1.8.

Habico Holding Group's financial risks, including its cash management and extension of credits, are managed centrally. The aim is to maintain a balanced risk profile.

Research and development activities

The Group have development activities covering both product and process development.

Management commentary

Statutory report on corporate social responsibility

Business Model

Habico Holding A/S is the holding company for Habico A/S, which is the holding company for Orifarm Group A/S, an ambitious operator in the European market for pharmaceuticals, where the ambition is to supply high quality pharmaceuticals at a lower price. Orifarm Group A/S consists of two main business areas: Orifarm Parallel Import and Orifarm Generics (Orifarm Group A/S). Furthermore, Habico A/S conduct other investment activities through Habico Invest A/S. For a more detailed description of the business model of Orifarm Group A/S please refer to www.orifarm.com/media/1835/orifarm_cop-rapport-2020.pdf.

CSR Policies

Habico Holding A/S and Orifarm Group A/S supports the 10 principles of the UN Global Compact. In 2018, Orifarm Group A/S joined the UN Global Compact, and has incorporated the principles into the strategies, policies and procedures, covering human rights, environment and climate protection, social and employee matters and anti-corruption. Habico Holding A/S follows the progress through its active ownership and board participation in Orifarm Group A/S. In this report, the CSR Report of Orifarm Group A/S outlining the policies, activities and results for 2020 can be found below.

Habico Holding A/S has not developed group CSR policies for its subsidiaries, or a separate formalized CSR policy for the investments, due to the extent of our investment activities in Habico Invest A/S. However, all investments are evaluated on the sustainability of their business and operations and acting in compliance with international law and conventions as well as having a high ethical and governance standard is a prerequisite.

CSR risk evaluation and mitigation

The principal CSR risks in the Group in terms of human rights, environment and climate protection, social and employee matters and anti-corruption are related to the activities in Orifarm Group A/S. The risk evaluation and mitigation procedures are described in the Orifarm CSR Report presented below at www.orifarm.com/media/1835/orifarm_cop-rapport-2020.pdf

Statutory report on the underrepresented gender

In Habico Holding A/S we believe, that diversity is very important to employees as well as to business. Consequently, the company is stressing internal efforts in the Group to constantly increase diversity across gender, age, and culture and hence to e.g. onboard and integrate employees of diverse ethnic backgrounds. We see the potential of each employee, and create opportunities for everyone to develop at work and contribute to our business, irrespective of their gender, age, ethnicity, disability, or other personal characteristics, and the level of internationalization in the Habico Holding Group has increased significantly in recent years.

The Board of Directors in Habico Holding A/S consists of 2 women and 4 men constituting an equal gender composition, cf. Danish Financial Statements Act sec. 99b. As Habico Holding A/S itself employs less than 50 people, there has not been adopted a specific policy for the underrepresented gender in management for the company. Neither has there been adopted a group policy or set group targets for gender diversity at boards in the subsidiaries.

Orifarm Group A/S has reported on its own gender diversity policy and board target in the CSR Report presented in www.orifarm.com/media/1835/orifarm_cop-rapport-2020.pdf

Management commentary

Events since the End of the Fiscal Year

From the reporting date until today, no events have occurred which could change the assessments made in the Annual Report.

In April 2020, the Group agreed to purchase a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products sold in Europe from Takeda Pharmaceutical Company Limited ("Takeda") for a purchase price of up to MEUR 615. The Group has acquired the rights for approximately 110 pharmaceuticals as well as 2 production sites.

The transaction was finalized by the end of March 2021.

Income statement for 2020

(1.000 EUR)

Parent				Group	
2019	2020		Note	2020	2019
0	0	Revenue	1	1.115.487	981.554
0	0	Other operating income		350	755
0	0	Cost of sales		-946.396	-831.582
0	0	Gross profit		169.441	150.727
-53	-90	Other external expenses	2	-49.420	-33.022
-235	-235	Staff costs	3	-68.656	-59.411
0	0	Depreciation, amortisation and impairment losses	4	-12.555	-11.509
-288	-325	Operating profit		38.810	46.785
34.609	27.550	Income from investments in group enterprises	5		
0	0	Income from investments in associates	6	-1.189	-1.351
359	1	Other financial income	7	10.660	5.675
-133	-2	Other financial expenses	8	-9.220	-5.800
34.547	27.224	Profit before tax		39.061	45.309
11	57	Tax on profit for the year	9	-11.780	-10.751
34.558	27.281	Profit for the year	10	27.281	34.558

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Balance sheet at 31.12.2020

(1.000 EUR)

Parent			Group		
2019	2020		Note	2020	2019
0	0	Development projects completed		5.566	3.871
0	0	Acquired licenses		13.429	13.177
0	0	Acquired intangible assets		4.735	3.011
0	0	Goodwill		55.577	57.195
0	0	Development projects in progress		9.054	5.055
0	0	Intangible assets	11	88.361	82.309
0	0	Land and buildings		29.739	20.223
0	0	Leasehold improvements		0	0
0	0	Plant and machinery		11.486	8.525
0	0	Property, plant and equipment	12	41.225	28.748
178.700	192.939	Investments in group enterprises	13		
0	0	Investments in associates	14	9.074	10.270
0	0	Receivables from associates	14	0	549
0	0	Other bonds and equity investments	14	21.788	14.378
178.700	192.939	Fixed asset investments		30.862	25.197
178.700	192.939	Fixed assets		160.448	136.254
0	0	Inventories	15	221.041	189.351
0	0	Trade Receivables		134.696	113.210
82	84	Receivables from group enterprises		0	0
0	0	Deferred tax	16	1.506	1.615
0	0	Other receivables		2.976	3.258
7	57	Tax receivable		6.643	1.578
0	0	Prepayments	17	6.501	1.448
89	141	Receivables		152.322	121.109
407	88	Cash		4.984	891
496	229	Current assets		378.347	311.351
179.196	193.168	Assets		538.795	447.605

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Habico Holding A/S

Balance sheet at 31.12.2020

(1.000 EUR)

Parent				Group	
2019	2020		Note	2020	2019
1.153	1.158	Contributed capital	18	1.158	1.153
0	0	Reserve for fair value adjustments		790	0
159.326	173.565	Reserve for net revaluation according to equity method		0	0
3.510	13.438	Retained earnings		186.213	162.836
15.200	5.000	Dividend		5.000	15.200
179.189	193.161	Equity		193.161	179.189
0	0	Deferred tax	16	9.003	6.586
0	0	Provisions		9.003	6.586
0	0	Mortgage debt		10.437	3.929
0	0	Bank debt		22.974	22.881
0	0	Other debt		3.375	1.027
0	0	Non-current liabilities other than provisions	19	36.786	27.837
0	0	Current portion of non-current liabilities other than provisions	19	665	545
0	0	Bank debt		185.642	135.189
0	0	Trade payables		42.906	39.459
0	0	Tax payable		6.525	1.839
7	7	Other payables		64.107	56.961
7	7	Current liabilities other than provisions		299.845	233.993
7	7	Liabilities other than provisions		336.631	261.830
179.196	193.168	Equity and liabilities		538.795	447.605
		Assets charged and collateral	20		
		Other Notes	21-29		

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Statement of changes in equity of 2020

(1.000 EUR)

	Group				
	Contributed capital	Reserve for fair value adjustments	Retained earnings	Proposed dividend	Total
Equity at 01.01.2020	1.153	0	162.836	15.200	179.189
Adjustment of hedging instruments	0	95	0	0	95
Exchange rate adjustments	5	695	9	0	709
Other entries on equity	0	0	1.087	0	1.087
Distributed dividend in the year	0	0	0	-15.200	-15.200
Profit for the year	0	0	22.281	5.000	27.281
Equity at 31.12.2020	1.158	790	186.213	5.000	193.161

	Parent				
	Contributed capital	Reserve for net revaluation according to equity method	Retained earnings	Proposed dividend	Total
Equity at 01.01.2020	1.153	159.326	3.510	15.200	179.189
Adjustment of hedging instruments	0	95	0	0	95
Exchange rate adjustments	5	707	-3	0	709
Other entries on equity	0	1.087	0	0	1.087
Distributed dividend in the year	0	0	0	-15.200	-15.200
Dividend from group enterprises	0	-15.200	15.200	0	0
Profit for the year	0	27.550	-5.269	5.000	27.281

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Cash flow statement for 2020

(1.000 EUR)

	Note	Group	
		2020	2019
Operating profit		38.810	46.785
Depreciation, amortisation and impairment losses		12.555	11.509
Exchange rate and hedging adjustments on equity		804	-93
Working capital changes	22	-47.354	-24.755
		4.815	33.446
Other financials, net		1.440	-125
Income taxes paid		-9.694	-12.055
Cash flows from operating activities		-3.439	21.266
Acquisition of intangible assets, property, plant and equipment		-35.472	-38.015
Acquisition of Financial Assets		-7.489	-13.150
Sale of property, plant and equipment		4.414	2.698
Change in deposits, fixed asset investments		549	-256
Cash flows from investing activities		-37.998	-48.723
Cash flows from operating and investing activities		-41.437	-27.457
Change in Non-current liabilities other than provisions, net		9.072	-9.077
Change in short term bank loans, net		50.453	43.256
Dividend received from associates		1.205	730
Dividend paid		-15.200	-10.044
Cash flow from financing activities		45.530	24.865
Increase/decrease in cash and cash equivalents		4.093	-2.592
Cash and equivalents 01.01.2020		891	106
Adjustment according to acquisition		0	3.377
Cash and equivalents 31.12.2020	23	4.984	891

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Notes

(1.000 EUR)

Parent		Group	
2019	2020	2020	2019
1. Revenue			
Activity information			
		1.015.631	898.615
		99.856	82.939
		1.115.487	981.554
2. Other external expenses			
53	90	35.172	32.322
0	0	14.248	700
53	90	49.420	33.022
3. Staff costs			
235	235	56.238	48.384
0	0	4.787	3.835
0	0	7.631	7.192
235	235	68.656	59.411
Here of:			
0	0	2.517	2.901
235	235	360	338
235	235	2.877	3.239
		1.178	1.111
Average number of employees			
<i>In addition, Group Executive Board participates in a Long Term Incentive Plan with share options (warrants) awarded in 2020. The warrants entitle the Group Executive Board to subscribe for shares for a total nominal value of EUR 17.2 thousand and should be exercised in 2025. The exercise price is in the range of EUR 142-187 thousand.</i>			
4. Depreciation, amortisation and impairment losses			
		2.110	1.933
		5.096	5.398
		1.055	1.125
		1.496	832
		711	663
		2.087	1.558
		12.555	11.509
5. Income from investments in group enterprises			
34.609	27.550		
34.609	27.550		
6. Income from investments in associates			
		-1.189	-1.351
		-1.189	-1.351

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Notes

(1.000 EUR)

Parent			Group	
2019	2020		2020	2019
7. Other financial income				
359	1	Financial income, group entities	0	0
0	0	Other financial income	10.660	5.675
359	1		10.660	5.675
8. Other financial expenses				
133	0	Financial expenses, group entities	0	0
0	2	Other financial expenses	9.220	5.800
133	2		9.220	5.800
9. Tax on profit for the year				
-11	-56	Current tax	8.675	9.886
0	0	Change in deferred tax	2.493	1.033
0	-1	Adjustments concerning previous years	612	-168
-11	-57		11.780	10.751
10. Distribution of profit				
	5.000	Proposed dividends	5.000	
	27.550	Reserve for net revaluation of equity holdings		
	-5.269	Retained earnings	22.281	
	27.281		27.281	

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Notes

(1.000 EUR)

Group

11. Intangible assets	Develop- ment projects completed	Acquired licenses	Acquired intangible assets	Goodwill	Development projects in progress	Total
Cost at 01.01.2020	7.728	40.115	15.771	72.825	5.055	141.494
Transfer	3.130	0	0	0	-3.130	0
Additions	262	4.799	2.813	450	7.571	15.895
Exchange rate adjustments	31	114	25	133	22	325
Disposals	-329	-952	0	-228	-464	-1.973
Cost at 31.12.2020	10.822	44.076	18.609	73.180	9.054	155.741
Amortization 01.01.2020	3.857	26.938	12.760	15.630	0	59.185
Amortization for the year	1.496	5.096	1.055	2.110	0	9.757
Exchange rate adjustments	18	137	59	43	0	257
Reversal relating to disposals	-115	-1.524	0	-180	0	-1.819
Amortization 31.12.2020	5.256	30.647	13.874	17.603	0	67.380
Carrying amount 31.12.2020	5.566	13.429	4.735	55.577	9.054	88.361
Carrying amount 31.12.2019	3.871	13.177	3.011	57.195	5.055	82.309

Development projects

Development projects consists of development of generic medicine. The development of the products are progressing as planned and are expected to be completed within 1-3 years.

The Entity is continually scanning for and developing new generic medicine. It is the managements opinion, that newly developed generic medicine will contribute with positive contribution margin in the future, on equal terms with the currently product portfolio.

Management continuously evaluates the value of development projects in progress, and write-down projects which are unprofitable.

Group

12. Property, plant and equipment	Land and buildings	Leasehold improve- ments	Plant and machinery	Total
Cost at 01.01.2020	25.655	918	15.889	42.462
Additions	10.156	0	9.421	19.577
Exchange rate adjustments	-8	2	-77	-83
Disposals	-9	0	-4.812	-4.821
Cost at 31.12.2020	35.794	920	20.421	57.135
Depreciation 01.01.2020	5.432	918	7.364	13.714
Depreciation for the year	711	0	2.087	2.798
Exchange rate adjustments	-18	2	-25	-41
Reversal relating to disposals	-70	0	-491	-561
Depreciation 31.12.2020	6.055	920	8.935	15.910
Carrying amount 31.12.2020	29.739	0	11.486	41.225
Carrying amount 31.12.2019	20.223	0	8.525	28.748

Notes

(1.000 EUR)

	Parent
	Investments in group enterprises
13. Fixed asset investment	
Cost at 01.01.2020	19.374
Cost at 31.12.2020	19.374
Net revaluation at 01.01.2020	159.326
Net share of profit/loss for the year	27.550
Dividend	-15.200
Adjustment of hedging on equity	95
Exchange rate adjustments	707
Other adjustments	1.087
Net revaluation 31.12.2020	173.565
Carrying amount 31.12.2020	192.939
Carrying amount 31.12.2019	178.700

Unamortised share of group goodwill on consolidation amounts 13.105 k.EUR.

Investments in group enterprises:	Country	Share
Habico A/S	Denmark	100%

See Group structure page 8

	Group		
	Investments in associates	Receivables from associates	Other equity investments
14. Investments in associates			
Cost at 01.01.2020	12.506	817	14.120
Transfer	-2.688	0	2.688
Additions	925	358	6.206
Exchange rate adjustments	30	0	59
Disposals	-1.344	0	-2.528
Cost at 31.12.2020	9.429	1.175	20.545
Value adjustment 01.01.2020	-2.236	-268	258
Transfer	2.675	0	-2.675
Value adjustment for the year	7	-907	3.660
Disposals/Dividend	-1.205	0	0
Profit for the year	-282	0	0
Reversal relating to disposals	686	0	0
Value adjustment 31.12.2020	-355	-1.175	1.243
Carrying amount 31.12.2020	9.074	0	21.788
Carrying amount 31.12.2019	10.270	549	14.378

Investments in associated entities:	Country	Share
New Start 1 ApS	Denmark	25,0%
MidCap T ApS	Denmark	38,1%
IQ Charter I A/S	Denmark	25,0%

See Group structure page 8

Details on investments which can harm the business has not been shown in accordance to section 97a(4) of the Danish Financial Statement Act

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Notes

(1.000 EUR)

Parent		Group	
2019	2020	2020	2019
15. Inventories			
		123.437	79.547
		96.782	92.087
		822	9.349
		0	8.368
		221.041	189.351
16. Deferred tax			
Deferred tax is incumbent on the following financial statement items:			
		4.352	2.682
		2.446	2.135
		264	254
		0	0
		435	-100
		7.497	4.971
Net value is recognised in the balance sheet as follows:			
		-1.506	-1.615
		9.003	6.586
		7.497	4.971
Development Deferred tax:			
		4.971	3.935
		2.505	1.033
		21	3
		7.497	4.971

17. Prepayments

Consists of prepayments on costs concerning subsequent financial year.

18. Contributed capital

The contributed capital consists of 8,612m shares at EUR 0,13442

The shares have not been divided into classes.

Besides a decrease in 2018 of 1.388 k.DKK (186 k.EUR), there has been no changes in the contributed capital.

In 2020, a subsidiary of the Company, issued a series of warrants, which in 2025 entitle the warrant holders to subscribe for shares in the subsidiary at a total nominal value of EUR 17.2 thousand. The exercise price varies for the series and is within the range EUR 142-187 thousand.

Notes

(1.000 EUR)

Group

	Due for payment within 1 year	Due for payment after 1 year	Amortized debt in total	Nominal debt in total
19. Non-current liabilities other than provisions				
Mortgage debt	596	10.437	11.033	11.033
Bank loans	0	22.974	22.974	22.974
Other debt	69	3.375	3.444	3.444
Non-current liabilities other than provisions 31.12.2020	665	36.786	37.451	37.451
Non-current liabilities other than provisions 31.12.2019	545	27.837	28.382	28.382
Due for payment after 5 years:				
Mortgage debt		8.084		
Other debt		3.141		
		11.225		

Group

	2020	2019
20. Assets charged and collateral		
Mortgage deeds and letter of indemnity have been issued as security for credit institutions with a nominal amount of	28.208	18.371
The actual liability on the balance sheet date amounts to	10.992	4.453
Carrying amount of pledged properties	27.532	16.007
Certain operating equipments have been financed by means of finance leases.		
Total operational lease obligation until contracts expire	3.283	3.414
Leasehold liabilities	9.837	6.924

Group:

The Group companies has provided inventories MEUR 25.0, as security for debt to the Group's banks and credit institutions.

The Group companies are a party to litigation regarding alleged infringements of trademark and patent rights. Management believes that these legal proceedings will not lead to material losses for the company.

There are pledged payments concerning investments in stocks and equity holdings. The maximum claim of payment is MEUR 8.4.

The Group has normal trade obligations on returned goods, and no significant losses are expected.

The entity has provided guarantees under which the guarantors assume joint and several liability for group companies net debt with bank and credit institution. Total net debt in relation to this guarantee is booked at MEUR 216.3 at 31 December 2020.

In addition, there are also security for the debt to banks and credit institutions, pledged unlisted shares in certain companies with a total book value per 31 December 2020 of MEUR 149.0.

Parent:

None.

21. Contingent liabilities**Parent:**

The parent company and the Danish Group companies are jointly taxed with all Danish subsidiaries, with HBS Capital ApS as the administration company. The parent Company and the danish group companies are therefore held liable under the Corporation Tax Act rules for income taxes, and if any obligations to withhold tax on interest, royalties and dividends for the jointly taxed companies.

Notes

(1.000 EUR)

	Group	
	2020	2019
22. Working capital changes		
Change in inventories (- = increase)	-31.690	-48.942
Change in receivables (- = increase)	-26.257	-12.334
Change in trade payables etc. (- = decrease)	10.593	32.810
Adjustment according to acquisition	0	3.711
	-47.354	-24.755
23. Cash and cash equivalents		
Cash	4.984	891
	4.984	891

24. Related parties with controlling interest

Related parties with controlling interest in Habico Holding A/S:

The following Companies own all the shares in the Entity, and therefore have a controlling influence on this:

- HBS Capital ApS, Central Business Registration No 41 00 08 80, Odense, Ultimate Parent company
- Hans Carl Bøgh-Sørensen, Odense, ultimate beneficial owner

Other related parties Habico Holding A/S has had transactions with in 2020:

The companies Board of Directors and Executive Board.

Fees etc. are separately disclosed in note 2, Staff costs.

All other transactions with related parties are eliminated in the overlying consolidated statements.

All transactions with related parties are carried out on arms length.

25. Ownership

The company has registered the following shareholders to hold more than 5% of the voting share capital or of the nominal value of the share capital:

- HBS Capital ApS, Energivej 15, 5260 Odense S.
- CHUCO Capital ApS, Energivej 15, 5260 Odense S.
- ACCO Capital ApS, Energivej 15, 5260 Odense S.
- ANHECO Capital ApS, Energivej 15, 5260 Odense S.

26. Group relations

Name and registered office of the Parent preparing consolidated financial statement for the ultimate group: HBS Capital ApS, Odense, Central Business Registration No 41 00 08 80.

	Group	
	2020	2019
27. Fees to auditors appointed at the Company's general meeting		
Fees are recognized under Other external expenses with:		
Fees for statutory audit	210	196
Fees for assurance engagements	21	10
Fees for tax advice	471	238
Fees for other services	891	324
	1.593	768

28. Exchange rate risk and financial instruments

As part of the hedge of recognized and unrecognized transactions, the Group uses hedging instruments in the form of forward exchange contracts. Hedge of recognized transactions primarily comprise receivables and payables. As at 31.12.2020 unrealized net losses on derivative financial instruments for currency hedging on Group level in total amounts TEUR 283. The amount is in the balance sheet included under other debt.

29. Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of the annual report.

In April 2020, Orifarm Group agreed to purchase a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products sold in Europe from Takeda Pharmaceutical Company Limited ("Takeda") for a purchase price of up to MEUR 615. Orifarm has acquired the rights for approximately 110 pharmaceuticals as well as 2 production sites.

The transaction was closed by the end of Takeda's Fiscal Year 2020 (31 March 2021).

Accounting policies

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large).

The accounting policies applied for these financial statements are consistent with those applied last year. The annual report is presented in EUR.

Income statement items are translated at the average rate for the year. Balance sheet items are translated at closing rate. The exchange rate adjustment from the average for the year, respectively, previous year's closing rate are posted directly to equity.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event, that future economic benefits will flow to the Group, and the value of the assets can be measured reliably.

Liabilities are recognised in the balance sheet when the Group has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Group, and the value of the liabilities can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

The consolidated financial statements

The consolidated financial statements include Habico Holding A/S (parent company) and companies (group enterprises) controlled by the parent, see the group overview page 8. The parent company is considered to have control when it directly or indirectly owns more than 50% of the voting rights or in other ways actually exercises controlling influence. Companies in which the Group directly or indirectly owns between 20% and 50% of the voting rights and exercises significant influence, but no controlling influence, are considered as associated companies. See the group overview page 8.

Consolidation principles

The consolidated financial statements are prepared on the basis of the financial statements for Habico Holding A/S and its subsidiaries. The consolidated financial statements are prepared by aggregation of uniform accounting items. On consolidation, elimination of intercompany revenue and expenses, and dividends as well as gains and losses on transactions between consolidated companies. The accounts used for consolidation are prepared in accordance with the groups accounting policies.

In the consolidated financial statement accounts of the subsidiaries are recognized 100%. Minority interests' proportionate share of net profit and net assets are presented as separate items in the income statement and balance sheet.

Business combinations

Newly acquired or newly established enterprises are recognised in the consolidated financial statements from the time of acquiring or establishing such enterprises. Divested or wound-up enterprises are recognised in the consolidated income statement up to the time of their divestment or windingup.

The purchase method is applied in the acquisition of new enterprises, under which identifiable assets and liabilities of these enterprises are measured at fair value at the acquisition date. On acquisition of enterprises, provisions are made for costs relating to decided and published restructurings in the acquired enterprise. Allowance is made for the tax effect of restatements.

Accounting policies

Positive differences in amount (goodwill) between cost of the acquired share and fair value of the assets and liabilities acquired are recognised under intangible assets, and they are amortised systematically in the income statement based on an individual assessment of their useful lives, however, no more than 40 years. Negative differences in amount (negative goodwill), corresponding to an estimated adverse development in the relevant enterprises, are recognised in the balance sheet as a separate item under deferred income, and they are recognised in the income statement as such adverse development is realised.

Profits or losses from divestment of equity investments

Profits or losses from divestment or winding-up of subsidiaries are calculated as the difference between selling price or settlement price and carrying amount of the net assets at the time of divestment or winding-up, inclusive of non-amortised goodwill and estimated expenses for divestment or winding-up.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date or the rate at the balance sheet date are recognised in the income statement as financial income or financial expenses. Property, plant and equipment, intangible assets, inventories and other non-monetary assets that have been purchased in foreign currencies are translated using historical rates.

On recognition of foreign subsidiaries which are independent units, all amounts are translated at the year-end rate. Differences in the exchange rate which arise when translating the foreign company's equity at the beginning of the year using the exchange rates at balance sheet date are recognised directly in equity.

Derivatives

On initial recognition in the balance sheet, derivative financial instruments are measured at cost and subsequently at fair value. Derivative financial instruments are recognised under other receivables or other payables, respectively.

Changes in the fair value of derivative financial instruments classified as and complying with the requirements for hedging of the fair value of a recognised asset or a recognised liability are recorded in the income statement together with changes in the value of the hedged asset or the hedged liability.

Changes in the fair value of derivative financial instruments classified as and complying with the requirements for hedging future transactions are classified directly on equity. When the hedged transactions are realised, the accumulated changes are recognised as part of cost of the relevant financial statement items.

For derivative financial instruments that do not qualify as hedging instruments, changes in fair market value are recognised currently in the income statement as financial income or financial expenses.

Changes in the fair value of derivative financial instruments applied for hedging net investments in independent foreign group enterprises or associates are classified directly as equity.

Income statement for 2020

Revenue

Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the determined consideration.

Other operating income

Other operating income comprises income of a secondary nature to the Group's primary activities.

Cost of sales

Cost of sales includes the consumption of commodities and freight costs that are incurred to generate the calculated revenue.

Accounting policies

Other external expenses

Other external expenses comprise expenses for distribution, sale, advertising, administration, premises, etc.

Staff costs

Staff costs comprise wages and salaries, social security costs, pension contributions, etc. for the Company's staff.

Income from investments in group enterprises and associates

Income from investments in group enterprises and associates comprises the pro rata share of the individual enterprises' profit/loss after full elimination of intra-group profits or losses.

Other financial income and expenses

These items comprise interest income and interest expenses, realised as well as unrealised capital gains and losses on liabilities and transactions in foreign currencies.

Tax on profit for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit/loss for the year and recognised directly in equity by the portion attributable to entries directly in equity. The portion of the tax taken to the income statement, which relates to extraordinary profit/loss for the year, is allocated to this entry whereas the remaining portion is taken to the year's profit/loss from ordinary activities.

Current tax payable or receivable is recognised in the balance sheet, stated as tax calculated on this year's taxable income, adjusted for prepaid tax.

Deferred tax is recognised on all temporary differences between the carrying amount and tax-based value of assets and liabilities, for which the tax-based value of assets is calculated based on the planned use of each asset.

Deferred tax is measured based on the tax regulations and tax rates of the relevant countries that will be in effect according to law at the balance sheet date when the deferred tax is estimated to be triggered as current tax. Changes in deferred tax resulting from changed tax rates are recognised in the income statement.

Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at their estimated realisable values, either as a set-off against deferred tax liabilities or as net tax assets.

The Parent is jointly taxed with all Danish subsidiaries and parent companies. The current Danish income tax is allocated among the jointly taxed companies proportionally to their taxable income (full allocation with a refund concerning tax losses).

The jointly taxed companies are subject to the rules of section 11B of the Danish Companies Act governing interest deduction limitation. It has been agreed in the joint taxation that reduced interest deduction is recognised in the company in which the interest deduction has been reduced.

Balance sheet at 31.12.2020

Development projects

Development costs comprises costs, staff costs and depreciations, directly associated to development activities.

Development projects, which are clearly defined and identifiable, and where the technical viability, resources and a potential future market can be established with the intention to produce, market or utilise the projects, are recognised in the balance sheet as intangible assets, if the cost are measured reliable, and there is a certain security, that the future profit will cover the production, marketing and administrations costs as well as development costs. Additional development costs are recognised in the income statement, as the costs occurs.

Development projects, are measured at cost less accumulated amortisation and impairment.

Accounting policies

When development projects are completed, the products are amortised straight-line over their expected useful lives calculated from the date when the product to which the development cost relate is introduced to the market. The amortisation period usually used is 5-10 years.

Acquired licenses

Files and application fees are measured at cost less accumulated amortisation and impairment losses.

Files and application fees regarding a specific product in relation to which a potential future market can be demonstrated and where the intention is to market the product in question are recognised as intangible assets. Other costs relating to applications are recognised as cost in the income statement as incurred.

Files and application fees regarding generic products are amortised straight-line over their expected useful lives calculated from the date when the product to which the files and application fees relate is introduced to the market. The amortisation period is 5-12 years.

When files and applications are subject to impairment, files and application fees are written down to the lower of recoverable amount and carrying amount.

Acquired intangible assets

Cost of development and implementation of major IT systems as well as other intangible assets is measured at cost with deduction of accumulated amortisation and impairment losses. The period of amortisation is usually 3-7 years.

When other intangible assets are subject to impairment, other intangible assets are written down to the lower of recoverable amount and carrying amount.

Goodwill

Goodwill is amortised straight-line over its estimated useful life which is fixed on the basis of the experience gained by Management for each business area.

The amortization period of goodwill is 10-40 years.

The determination of the lifetime is decided based on an evaluation of a combined company with Know How, skills and a efficient organization, which is expected to provide development of the business in a long time to come, and because the lifetime of the medicinal products normally are very long.

When goodwill is subject to impairment, goodwill is written down to the lower of recoverable amount and carrying amount.

Land and buildings, leasehold improvements and plant and machinery

Land and buildings, leasehold improvements and plant and machinery are measured at cost less accumulated depreciation and impairment losses. Land is not depreciated.

Cost comprises the acquisition price, costs directly attributable to the acquisition, and preparation costs of the asset until the time when it is ready to be put into operation. Interest expenses are not included in cost.

The basis of depreciation is cost less estimated residual value after the end of useful life. The residual value amounts to 40% of the acquisition price. Straight-line depreciation is made on the basis of the following estimated useful lives of the assets:

Buildings:	10-50 years
Leasehold improvements:	5-10 years
Plant and machinery:	3-10 years

Estimated useful lives and residual values are reassessed annually.

When property, plant and equipment are subject to impariment, PPE are written down to the lower of recoverable amount and carrying amount.

Profits and losses from the sale of property, plant and equipment are calculated as the difference between selling price less selling costs and the carrying amount at the time of sale. Profit or loss is recognised in the income statement.

Accounting policies

Investments in group enterprises and associates

Investments in group enterprises and associated enterprises are recognised and measured under the equity method. This means that investments are measured at the pro rata share of the enterprises' equity plus or minus unamortised goodwill or negative goodwill on consolidation and plus or minus unrealised intra-group profits and losses.

The Parent's share of the enterprises' profits or losses after elimination of unrealised intra-group profits and losses and plus or minus amortisation of positive, or negative, goodwill on consolidation is recognised in the income statement.

Group enterprises and associated enterprises with negative equity are measured at zero value, and any receivables from these enterprises are written down by the Parent's share of such negative equity if it is deemed irrecoverable. If the negative equity value exceeds the amount receivable, the remaining amount is recognised under provisions if the Parent has a legal or constructive obligation to cover the liabilities of the relevant enterprise.

Net revaluation of investments in group and associated enterprises is taken to reserve for net revaluation under the equity method if the carrying amount exceeds cost.

The purchase method is applied in the acquisition of investments in group and associated enterprises; see above description under consolidated financial statements.

Details on investments which can harm the business has not been shown in accordance to section 97a(4) of the Danish Financial Statement Act

Inventories

Inventories are measured at the lower of cost using the FIFO method and net realisable value.

Cost of goods for resale, raw materials and consumables consists of purchase price plus landing costs. Cost of manufactured goods and work in progress consists of costs of raw materials, consumables and direct labour costs as well as indirect production costs.

Indirect production costs comprise indirect materials and labour costs, costs of maintenance of and depreciation and impairment losses on machinery, factory buildings and equipment applied for the manufacturing process as well as costs of factory administration and management. Finance costs are not included in cost.

The net realisable value of inventories is calculated as the estimated selling price less completion costs and costs incurred to execute sale.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less write-downs for bad receivables.

Prepayments

Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.

Cash

Cash comprises cash in hand and bank deposits.

Bank loans

Bank debt comprises debt to banks.

Mortgage debt

At the time of borrowing, mortgage debt is measured at cost which corresponds to the proceeds received less transaction costs incurred. The mortgage debt is subsequently measured at amortised cost. This means that the difference between the proceeds at the time of borrowing and the nominal amount of the loan is recognised in the income statement as a financial expense over the term of the loan applying the effective interest method.

Other financial liabilities

Other financial liabilities are measured at amortized cost, usually equaling nominal value of the liability.

Accounting policies

Operating lease commitments

Lease payments on operating leases are recognised on an ongoing basis in the income statement over the term of the lease.

Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity.

Cash flow statement

The cash flow statement of the Group is presented using the indirect method and shows cash flows from operating, investing and financing activities as well as the Group's cash and cash equivalents at the beginning and the end of the financial year. No separate cash flow statement has been prepared for the Parent because it is included in the consolidated cash flow statement.

Cash flows from acquisition and divestment of enterprises are shown separately under cash flows from investing activities. Cash flows from acquired enterprises are recognised in the cash flow statement from the time of their acquisition, and cash flows from divested enterprises are recognised up to the time of sale.

Cash flows from operating activities are calculated as the operating profit/loss adjusted for non-cash operating items, working capital changes and income taxes paid.

Cash flows from investing activities comprise payments in connection with acquisition and divestment of enterprises, activities and fixed asset investments as well as acquisition, development, improvement and sale, etc of intangible assets and property, plant and equipment.

Cash flows from financing activities comprise changes in the size or composition of the Parent's share capital and related costs as well as the raising of loans, inception of finance leases, instalments on interest-bearing debt, purchase of treasury shares, and payment of dividend.

Cash and cash equivalents comprise cash and short-term securities with an insignificant price risk less short-term bank debt.

Segment information

No geographical segment information is specified in the annual report. The information has been omitted, as the information may give rise significant damage to the company, cf. Section 96 (1) of the Danish Financial Statements Act.

Financial highlights

Financial highlights are calculated as follows:

Gross margin:	$\frac{\text{Gross profit} \times 100}{\text{Revenue}}$
Operating margin:	$\frac{\text{Operating income} \times 100}{\text{Revenue}}$
Equity ratio:	$\frac{\text{Equity} \times 100}{\text{Total assets}}$
Return on equity:	$\frac{\text{Profit for the year} \times 100}{\text{Average equity}}$

PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift.
Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

Navnet er skjult (CPR valideret)

Bestyrelsesmedlem

Serienummer: PID:9208-2002-2-968418718281

IP: 87.49.xxx.xxx

2021-06-29 10:39:47Z

NEM ID 

Ole Michael Friis

Bestyrelsesmedlem

Serienummer: PID:9208-2002-2-015337804743

IP: 94.126.xxx.xxx

2021-06-29 10:46:32Z

NEM ID 

Navnet er skjult (CPR valideret)

Bestyrelsesmedlem

Serienummer: PID:9208-2002-2-321197939931

IP: 178.117.xxx.xxx

2021-06-29 10:49:39Z

NEM ID 

Navnet er skjult (CPR valideret)

Bestyrelsesformand

Serienummer: PID:9208-2002-2-127722975949

IP: 89.239.xxx.xxx

2021-06-29 10:53:02Z

NEM ID 

Navnet er skjult (CPR valideret)

Dirigent

Serienummer: PID:9208-2002-2-127722975949

IP: 89.239.xxx.xxx

2021-06-29 10:53:02Z

NEM ID 

Nikolaj Thomsen

Revisor

Serienummer: PID:9208-2002-2-256851643530

IP: 217.63.xxx.xxx

2021-06-29 12:32:01Z

NEM ID 

Christian Ulrik Bøgh-Sørensen (CPR valideret)

Bestyrelsesmedlem

Serienummer: PID:9208-2002-2-381858183740

IP: 80.161.xxx.xxx

2021-06-29 14:48:56Z

NEM ID 

Jens Serup

Revisor

Serienummer: CVR:33963556-RID:97983395

IP: 188.177.xxx.xxx

2021-06-29 15:34:29Z

NEM ID 

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstempelt med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service** <penneo@penneo.com>. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validate>

PENNEO

Underskrifterne i dette dokument er juridisk bindende. Dokumentet er underskrevet via Penneo™ sikker digital underskrift.
Underskrivernes identiteter er blevet registreret, og informationerne er listet herunder.

“Med min underskrift bekræfter jeg indholdet og alle datoer i dette dokument.”

Birgitte Bøgh-Sørensen (CPR valideret)

Adm. direktør

Serienummer: PID:9208-2002-2-360350289028

IP: 37.120.xxx.xxx

2021-06-29 16:55:55Z

NEM ID 

Birgitte Bøgh-Sørensen (CPR valideret)

Bestyrelsesmedlem

Serienummer: PID:9208-2002-2-360350289028

IP: 37.120.xxx.xxx

2021-06-29 16:55:55Z

NEM ID 

Penneo dokumentnøgle: Z1E7H-C1FCA-EAD8Z-6F4XH-DZ4GB-3ESKU

Dette dokument er underskrevet digitalt via **Penneo.com**. Signeringsbeviserne i dokumentet er sikret og valideret ved anvendelse af den matematiske hashværdi af det originale dokument. Dokumentet er låst for ændringer og tidsstempelt med et certifikat fra en betroet tredjepart. Alle kryptografiske signeringsbeviser er indlejret i denne PDF, i tilfælde af de skal anvendes til validering i fremtiden.

Sådan kan du sikre, at dokumentet er originalt

Dette dokument er beskyttet med et Adobe CDS certifikat. Når du åbner dokumentet

i Adobe Reader, kan du se, at dokumentet er certificeret af **Penneo e-signature service** <penneo@penneo.com>. Dette er din garanti for, at indholdet af dokumentet er uændret.

Du har mulighed for at efterprøve de kryptografiske signeringsbeviser indlejret i dokumentet ved at anvende Penneos validator på følgende websted: <https://penneo.com/validate>